New drug aims to boost stroke recovery in major trial
NCT ID NCT07241520
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This large Phase 3 trial is testing whether an investigational drug called SHPL-49 can help people recover better after an acute ischemic stroke. About 1,096 participants will receive either the drug or a placebo as an IV infusion twice daily for 7 days, alongside standard care. The main goal is to see if more people achieve functional independence (able to carry out daily activities) 90 days after the stroke.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHPL-49 injection (a drug given intravenously)
- What this could lead to
- If successful, this could provide a new treatment option to improve recovery and reduce disability after a stroke.
- What could go wrong
- This is a Phase 3 trial, but the drug is still experimental. It may not prove more effective than placebo, and there could be unknown side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Linfen Central Hospital
RECRUITINGLinfen, Shanxi, 041000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict stroke recovery?
- Can a drug boost brain recovery after stroke?
- Can a blood Clot's inflammation predict stroke recovery?
- Can a new infusion drug boost stroke recovery?
- Can removing clots from tiny brain arteries boost stroke recovery?
- Could vague stroke symptoms delay lifesaving treatment?